X-Linked Recessive Ichthyosis (XLRI) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
X-Linked Recessive Ichthyosis (XLRI) Market Outlook
Thelansis’s “X-Linked Recessive
Ichthyosis (XLRI) Market Outlook, Epidemiology, Competitive Landscape, and
Market Forecast Report – 2024 To 2034" covers disease overview,
epidemiology, drug utilization, prescription share analysis, competitive
landscape, clinical practice, regulatory landscape, patient share, market
uptake, market forecast, and key market insights under the potential X-Linked
Recessive Ichthyosis (XLRI) treatment modalities options for eight major
markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
X-Linked Recessive Ichthyosis (XLRI)
Overview
X-linked
ichthyosis (XLI) is a skin disorder caused by a genetic deficiency in the STS
gene located on the X chromosome. This leads to abnormal shedding of the skin,
resulting in dry and scaly skin with polygonal scales. The condition is
typically diagnosed in the first year of life, with some cases manifesting at
birth. However, the flexures, palms, and soles remain unaffected, as do the
hair and nails. Most XLI patients have partial or complete deletions of the STS
gene, resulting in extensive scaling. However, point mutations can also cause
complete deficiency in STS. Female carriers of STS do not show symptoms because
of the gene’s location on the X chromosome. De novo STS mutations can also
occur. XLI is mainly differentiated from ichthyosis vulgaris and other types of
ichthyosis, such as lamellar ichthyosis. Ichthyosis vulgaris is inherited in an
autosomal dominant pattern, with symmetrical light grey scaling typically
appearing after three months of age. Flexion zones are affected, but not the
palms, soles, and hair.
Geography coverage:
G8 (United States, EU5 [France,
Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by robust
research, including:
- In-depth interviews with leading KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR datasets
- Secondary research (e.g., peer-reviewed journal
articles, third-party research databases)
Deliverables format and
updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS Excel-based automated
dashboard)
- Epidemiology (MS Excel; interactive tool)
- Executive Insights (PowerPoint presentation)
- Others: regular updates, customizations, consultant
support
*As per Thelansis’s policy, we
ensure that we include all the recent updates before releasing the report
content and market model.
Salient features of Market
Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market forecasts validated
through the top-down sales methodology
- Covers clinically and commercially-relevant patient
populations/ line of therapies
- Annualized drug-level sales and patient share
projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources & assumptions
- Graphical and tabular outputs
- Users can customize the model based on requirements
Key business questions answered:
- How can drug development and lifecycle management
strategies be optimized across G8 markets (US, EU5, Japan, and China)?
- How large is the patient population in terms of
incidence, prevalence, segments, and those receiving drug treatments?
- What is the 10-year market outlook for sales and
patient share?
- Which events will have the greatest impact on the
market’s trajectory?
- What insights do interviewed experts provide on
current and emerging treatments?
- Which pipeline products show the most promise, and
what is their potential for launch and future positioning?
- What are the key unmet needs and KOL expectations for
target profiles?
- What key regulatory and payer requirements must be
met to secure drug approval and favorable market access?
- and more…
Comments
Post a Comment